These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
233 related articles for article (PubMed ID: 16710741)
1. Recombined DNA vaccines encoding calreticulin linked to HPV6bE7 enhance immune response and inhibit angiogenic activity in B16 melanoma mouse model expressing HPV 6bE7 antigen. Zhao KJ; Cheng H; Zhu KJ; Xu Y; Chen ML; Zhang X; Song T; Ye J; Wang Q; Chen DF Arch Dermatol Res; 2006 Jul; 298(2):64-72. PubMed ID: 16710741 [TBL] [Abstract][Full Text] [Related]
2. [The construction and immune response of fusion DNA vaccine CRT180/HPV6E7]. Zhao KJ; Cheng H; Xu Y; Zhu KJ; Chen ML; Zhang X; Song T; Wang Q; Chen DF Sichuan Da Xue Xue Bao Yi Xue Ban; 2007 Jul; 38(4):573-7. PubMed ID: 17718414 [TBL] [Abstract][Full Text] [Related]
3. [HPV DNA vaccines expressing recombinant CRT/HPV6bE7 fusion protein inhibit tumor growth and angiogenic activity]. Xu Y; Cheng H; Zhao KJ; Zhu KJ; Zhang X Bing Du Xue Bao; 2007 Nov; 23(6):466-70. PubMed ID: 18092684 [TBL] [Abstract][Full Text] [Related]
4. Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen. Cheng WF; Hung CF; Chai CY; Hsu KF; He L; Ling M; Wu TC J Clin Invest; 2001 Sep; 108(5):669-78. PubMed ID: 11544272 [TBL] [Abstract][Full Text] [Related]
5. Comparison of HPV DNA vaccines employing intracellular targeting strategies. Kim JW; Hung CF; Juang J; He L; Kim TW; Armstrong DK; Pai SI; Chen PJ; Lin CT; Boyd DA; Wu TC Gene Ther; 2004 Jun; 11(12):1011-8. PubMed ID: 14985791 [TBL] [Abstract][Full Text] [Related]
6. Enhancement of vaccinia vaccine potency by linkage of tumor antigen gene to gene encoding calreticulin. Hsieh CJ; Kim TW; Hung CF; Juang J; Moniz M; Boyd DA; He L; Chen PJ; Chen CH; Wu TC Vaccine; 2004 Sep; 22(29-30):3993-4001. PubMed ID: 15364449 [TBL] [Abstract][Full Text] [Related]
7. An improved rearranged Human Papillomavirus Type 16 E7 DNA vaccine candidate (HPV-16 E7SH) induces an E7 wildtype-specific T cell response. Ohlschläger P; Pes M; Osen W; Dürst M; Schneider A; Gissmann L; Kaufmann AM Vaccine; 2006 Apr; 24(15):2880-93. PubMed ID: 16472545 [TBL] [Abstract][Full Text] [Related]
8. DNA vaccine encoding heat shock protein 60 co-linked to HPV16 E6 and E7 tumor antigens generates more potent immunotherapeutic effects than respective E6 or E7 tumor antigens. Huang CY; Chen CA; Lee CN; Chang MC; Su YN; Lin YC; Hsieh CY; Cheng WF Gynecol Oncol; 2007 Dec; 107(3):404-12. PubMed ID: 17905417 [TBL] [Abstract][Full Text] [Related]
9. Characterization of HPV-16 E6 DNA vaccines employing intracellular targeting and intercellular spreading strategies. Peng S; Trimble C; Ji H; He L; Tsai YC; Macaes B; Hung CF; Wu TC J Biomed Sci; 2005 Oct; 12(5):689-700. PubMed ID: 16200349 [TBL] [Abstract][Full Text] [Related]
10. A DNA vaccine encoding a codon-optimized human papillomavirus type 16 E6 gene enhances CTL response and anti-tumor activity. Lin CT; Tsai YC; He L; Calizo R; Chou HH; Chang TC; Soong YK; Hung CF; Lai CH J Biomed Sci; 2006 Jul; 13(4):481-8. PubMed ID: 16649071 [TBL] [Abstract][Full Text] [Related]
11. Modified HPV16 E7/HSP70 DNA vaccine with high safety and enhanced cellular immunity represses murine lung metastatic tumors with downregulated expression of MHC class I molecules. Li H; Ou X; Xiong J Gynecol Oncol; 2007 Mar; 104(3):564-71. PubMed ID: 17081598 [TBL] [Abstract][Full Text] [Related]
12. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control. Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230 [TBL] [Abstract][Full Text] [Related]
13. DNA vaccines against HPV-16 E7-expressing tumour cells. De Marco F; Hallez S; Brulet JM; Gesché F; Marzano P; Flamini S; Marcante ML; Venuti A Anticancer Res; 2003; 23(2B):1449-54. PubMed ID: 12820408 [TBL] [Abstract][Full Text] [Related]
14. Plasmid encoding papillomavirus Type 16 (HPV16) DNA constructed with codon optimization improved the immunogenicity against HPV infection. Cheung YK; Cheng SC; Sin FW; Xie Y Vaccine; 2004 Dec; 23(5):629-38. PubMed ID: 15542183 [TBL] [Abstract][Full Text] [Related]
15. A DNA vaccine constructed with human papillomavirus type 16 (HPV16) E7 and E6 genes induced specific immune responses. Yan Q; Cheung YK; Cheng SC; Wang XH; Shi M; Hu MH; Yong X Gynecol Oncol; 2007 Jan; 104(1):199-206. PubMed ID: 17049969 [TBL] [Abstract][Full Text] [Related]
16. Secretory heat-shock protein as a dendritic cell-targeting molecule: a new strategy to enhance the potency of genetic vaccines. Hauser H; Shen L; Gu QL; Krueger S; Chen SY Gene Ther; 2004 Jun; 11(11):924-32. PubMed ID: 15085173 [TBL] [Abstract][Full Text] [Related]
17. [Novel vaccines against M. tuberculosis]. Okada M Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920 [TBL] [Abstract][Full Text] [Related]
18. Comparison of DNA- and mRNA-transfected mouse dendritic cells as potential vaccines against the human papillomavirus type 16 associated oncoprotein E7. Dell K; Klein C; Gissmann L Antivir Ther; 2008; 13(4):495-509. PubMed ID: 18672528 [TBL] [Abstract][Full Text] [Related]
19. Optimal induction of HPV DNA vaccine-induced CD8+ T cell responses and therapeutic antitumor effect by antigen engineering and electroporation. Seo SH; Jin HT; Park SH; Youn JI; Sung YC Vaccine; 2009 Sep; 27(42):5906-12. PubMed ID: 19651174 [TBL] [Abstract][Full Text] [Related]
20. Enhancement of DNA vaccine potency through linkage of antigen gene to ER chaperone molecules, ER-60, tapasin, and calnexin. Lin CT; Chang TC; Chao A; Dzeng E; Soong YK; Hung CF; Lai CH J Biomed Sci; 2005; 12(2):279-87. PubMed ID: 15918000 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]